Hinge Health valuation reset from $6.2B

The reset showed that public investors valued Hinge Health less like a 2021 growth story and more like a healthcare company that still had to prove durable scale. Its October 2021 private round set a $6.2B mark during the peak digital health funding cycle, while the May 2025 IPO priced at $32 a share and the first day close implied about a $3B market cap, or less than half that peak. That gap reflected a market shift from rewarding category leadership to demanding public proof on revenue, margins, and repeatable outcomes.1 2 3 4

• The private valuation was set in a very different market. Hinge raised a $400M Series E in October 2021 at $6.2B, part of the pandemic era boom when investors aggressively priced digital health leaders on future category size rather than near term public market comparables.2 5
• By the IPO, pricing discipline had tightened. Hinge sold 13.666M shares at $32 in May 2025, and the stock closed its first trading day at $37.56 for an approximate $3B market cap. That still signaled demand, but at a much lower baseline than the last private round.1 3
• The reset did not mean the business had stalled. Hinge reached about $390.4M in 2024 revenue, up 33.4% year over year, which helps explain why the stock later recovered. The public market simply started from a lower entry point and waited for execution to close the gap.4

Going forward, the important question is not whether Hinge can get back to its old private mark, but whether it can grow into a durable public healthcare multiple. If revenue keeps compounding and the company expands beyond core musculoskeletal care without losing margins, the IPO reset will look less like a haircut and more like a public market re underwriting of the business.3 4